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Hepatitis C virus: treatment 
options and cost
Hepatitis C virus (HCV) is an enveloped 
positive strand RNA virus that infects up to 
150 million individuals worldwide. HCV- 
infected individuals are at increased risk of 
developing cirrhosis and hepatocellular car-
cinoma. The economic burden of HCV in 
the US alone is estimated to be $6.5 billion 
annually with increasing annual costs pro-
jected through at least 2024 (1). Treatment 
strategies have centered on antiviral drugs, 
such as ribavirin and type I interferons (2); 
however, HCV exists as a quasispecies that 
includes a variety of genotypes that are dif-
ferentially susceptible to these regimens. 
Currently, 6 genotypes are recognized, with 
varying numbers of subspecies within each 
of these 6 clades. Recently, the drug sofos-
buvir, a nonstructural protein 5B (NS5B) 
RNA polymerase inhibitor, was approved 
for use in combination with ribavirin to 
treat HCV genotypes 2 and 3. Sofosbuvir 
is also approved for use in combination 
with ribavirin and pegylated interferon for 
use against HCV genotypes 2 and 4. These 
regimens have been shown to achieve up 
to 90% response rates in patients, particu-
larly in those infected with HCV genotype 
1 or 2 (2). The newest FDA-approved oral 
regimen, which consists of ledipasvir (a 
NS5A inhibitor) and sofosbuvir, achieved 
up to 99% cure rate in noncirrhotic patients 
infected with HCV genotype 1 after 12 
weeks of treatment (3).
The search for an effective 
vaccine
Although much progress has been made 
in treating HCV, the development of a pre-
ventative vaccine remains a major goal in 
the field. The basis for HCV vaccination 
is that patients will develop neutralizing 
antibodies that target HCV viral envelope 
proteins, thereby inhibiting viral entry 
into host cells. Multiple monoclonal anti-
bodies with demonstrated ability to neu-
tralize viral attachment or entry into host 
cells have been produced (4); however, 
HCV has a propensity for immune escape, 
which is associated with the acquisition of 
mutations in the targeted region of HCV 
envelope proteins, such as E2 (5). In this 
issue, Bailey et al. (6) provide new insight 
into strategies used by HCV for immune 
escape that will need to be considered for 
future rational vaccine design.
Specifically, Bailey and colleagues (6) 
studied the issue of immune escape across 
a number of HCV envelope–directed 
monoclonal antibodies and tested these 
using a panel of human embryonic kidney 
cell lines (7) that express different HCV 
pseudoparticles (HCVpp) encoding nat-
urally occurring E1 and E2 variants from 
HCV genotype 1. The HCVpp-expressing 
kidney cell library consisted of nineteen 
clones, and eighteen different monoclonal 
antibodies were screened for their neu-
tralization ability. Two of the antibodies 
tested, HC84.26 and AR4A, had the great-
est potency and were able to neutralize 
nearly 90% of the clones. The sensitivity 
of the different HCVpp-expressing clones 
to the monoclonal antibody panel varied; 
however, some clones were extremely 
resistant to highly effective monoclonal 
antibodies, including HC84.26.
Bailey et al. (6) then evaluated the 
envelope proteins in the HCVpp-express-
ing clones that were resistant or sensitive 
to neutralization by monoclonal antibodies 
with known HCV envelope-binding sites. 
In addition to mutations within the anti-
body-binding regions of E2, the authors 
also observed clusters of resistance that 
mapped to parts of the viral envelope that 
were distinct from known epitopes and 
that these clustered in relation to the neu-
tralization resistance/susceptibility profile 
of the different HCVpp-expressing clones. 
Together, these data suggest that genetic 
alterations in envelope proteins that are 
distinct from known antibody-binding 
epitopes may confer resistance to anti-
body-mediated neutralization. Resistance 
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Hepatitis C virus (HCV) is a leading cause of chronic liver disease, and efforts 
to develop therapeutic vaccine strategies have been limited by immune 
escape due to HCV variants that are resistant to current vaccines or HCV 
variants that rapidly acquire new resistance-conferring mutations. Recently, 
the crystal structure of the viral envelope protein E2 region was resolved 
as well as how E2 docks to the host CD81 protein; therefore, antibodies 
that block this interaction should prevent viral entry into host cells. In this 
issue of the JCI, Bailey and colleagues show that immune escape of HCV 
can occur by naturally occurring polymorphisms in E2 that are distinct from 
those at mapped sites of antibody binding. These data reveal alternative 
mechanisms of resistance that need to be considered in both natural viral 
escape as well as in rationale vaccine design against HCV.
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peutic vaccination or to develop broadly 
effective therapeutic monoclonal antibod-
ies more difficult. Based on the propen-
sity of immune escape, it is unlikely that 
a vaccine directed against just one region 
of the HCV envelope will prove effective. 
This type of multivalent approach to vac-
cine generation would be similar to the 
approach used for pneumococcal immuni-
zation, which provides protection against 
multiple pneumococcal serotypes but does 
not protect against all strains. Potential 
multivalent HCV vaccines would consist 
of the most common viral E1E2 variants 
based on viral genomics. A multivalent 
approach to HCV immunization will be 
costly, based on both production costs as 
well as chemistry, manufacturing, and 
controls costs, which would be required 
to ensure the safety of each vaccine com-
ponent. The work by Baily et al. (6) clearly 
demonstrates that monoclonal antibody 
approaches may not be feasible to provide 
broad HCV protection, as even bispecific 
antibodies would likely encounter immune 
escape. The study by Bailey and colleagues 
does provide a platform through which 
new antibodies can be screened. This type 
of cell-based platform to test the efficacy 
of vaccine candidates in their ability to 
neutralize a variety of HCVpp will clearly 
benefit future clinical development. We 
are currently in an era in which treatment 
for HCV-infected individuals has reached 
new heights in therapeutic efficacy. Fur-
ther work on identifying envelope variants 
will hopefully help realize the potential of 
an HCV vaccine.
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mapped to a region in E2 that encom-
passes amino acids 416–560, which span 
the front layer, the CD81-binding motif, 
and the central β-sheet region of the 
envelope. Specifically, polymorphisms in 
amino acids 431, 442, and 560 resulted in 
limited resistance to the antibody panel; 
however, mutations in the central β-sheet 
(amino acids 526–569) conferred broad 
resistance to the antibodies tested. Anal-
ysis of the envelope proteins expressed 
by susceptible clones and the envelope 
proteins expressed by resistant HCVpp-
expressing clones revealed 7 shared variant 
sites. Introduction of resistance-associated 
mutations into susceptible HCV envelops 
conferred neutralization resistance, and 
introduction of susceptibility-associated 
mutations in resistant envelopes resulted in 
sensitivity to antibody neutralization. Bai-
ley and colleagues (6) identified three crit-
ical mutations (I538V, Q546L, and T563V) 
that mediate resistance to both monoclo-
nal antibodies and polyclonal antibod-
ies. Importantly, these mutations were 
not in areas of the envelope that mapped 
to monoclonal antibody-binding sites. 
Although some of these mutations may 
confer some negative effect on viral fit-
ness, the identification of these mutations 
may also explain HCV immune escape. 
The exact mechanisms of resistance con-
ferred by these mutations are currently not 
known but may involve alterations in pro-
tein folding or glycosylation, which could 
mask epitopes or create steric hindrance 
and thereby reduce antibody binding. In 
addition, receptor-independent transfer of 
replication-competent HCV RNA by exo-
somes may also undermine the efficacy of 
antibody-mediated protection (8). Future 
studies will need to focus on how these dif-
ferent mutations confer resistance and the 
overall contribution of exosome-mediated 
viral entry in immune escape.
Conclusions and future 
directions
The level of polymorphisms within the 
HCV envelope that confer antibody resis-
tance makes strategies to achieve thera-
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